Amended AMNOG Sees New Life Breathed Into Trajenta Reimbursement Bid In Germany
This article was originally published in The Pink Sheet Daily
Changes to Germany’s drug reimbursement law have permitted Boehringer Ingelheim and Eli Lilly to submit an updated dossier for their oral therapy Trajenta, giving medicine makers who operate there hope that further positive amendments will occur.
You may also be interested in...
AstraZeneca’s Caprelsa has failed to take advantage of a second assessment chance at IQWiG, and it seems clear the company and the assessor never saw eye-to-eye on trial design.
Germany’s IQWiG has tightened the screw on reimbursement submissions, rejecting Bayer’s Eylea for AMD on technical grounds concerning its comparator.
In the two years since Germany’s reimbursement process for new drugs turned Europe’s largest market into one of the toughest, the impact on pricing hasn’t been as bad as many expected. But there’s more to come, with several on-market categories slated for retrospective review, and even mandatory rebates could follow.